[go: up one dir, main page]

WO2015183984A3 - Therapeutic compositions including tocopherol and uses thereof - Google Patents

Therapeutic compositions including tocopherol and uses thereof Download PDF

Info

Publication number
WO2015183984A3
WO2015183984A3 PCT/US2015/032715 US2015032715W WO2015183984A3 WO 2015183984 A3 WO2015183984 A3 WO 2015183984A3 US 2015032715 W US2015032715 W US 2015032715W WO 2015183984 A3 WO2015183984 A3 WO 2015183984A3
Authority
WO
WIPO (PCT)
Prior art keywords
phe
lys
arg
aromatic
tocopherol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/032715
Other languages
French (fr)
Other versions
WO2015183984A2 (en
Inventor
D. Travis Wilson
Mark BAMBERGER
Peter OATES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stealth Peptides International Inc
Original Assignee
Stealth Peptides International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides International Inc filed Critical Stealth Peptides International Inc
Publication of WO2015183984A2 publication Critical patent/WO2015183984A2/en
Publication of WO2015183984A3 publication Critical patent/WO2015183984A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of tocopherol, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a tocopherol and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2',6'- dimethyl-Tyr-D-Arg-Phe-Lys-NH2, Phe-D-Arg-Phe-Lys-NH2, or D-Arg-2',6'-Dmt-Lys-Phe-NH2.
PCT/US2015/032715 2014-05-28 2015-05-27 Therapeutic compositions including tocopherol and uses thereof Ceased WO2015183984A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462003757P 2014-05-28 2014-05-28
US62/003,757 2014-05-28

Publications (2)

Publication Number Publication Date
WO2015183984A2 WO2015183984A2 (en) 2015-12-03
WO2015183984A3 true WO2015183984A3 (en) 2016-04-07

Family

ID=54700044

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/032715 Ceased WO2015183984A2 (en) 2014-05-28 2015-05-27 Therapeutic compositions including tocopherol and uses thereof

Country Status (1)

Country Link
WO (1) WO2015183984A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106803A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2018223032A1 (en) * 2017-06-02 2018-12-06 Stealth Biotherapeutics Corp. Crystalline salt forms of sbt-20
JP7606966B2 (en) 2018-12-18 2024-12-26 ステルス バイオセラピューティクス インコーポレイテッド Analogs targeting mitochondrial diseases
WO2020236802A1 (en) * 2019-05-20 2020-11-26 Poviva Corp. Compositions comprising biologically active agents and bile salts

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153890A1 (en) * 2001-10-05 2005-07-14 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20090202481A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same
WO2014022551A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
US8697657B2 (en) * 2010-03-15 2014-04-15 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153890A1 (en) * 2001-10-05 2005-07-14 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20090202481A1 (en) * 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US8697657B2 (en) * 2010-03-15 2014-04-15 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
WO2014022551A1 (en) * 2012-08-02 2014-02-06 Stealth Peptides International, Inc. Methods for treatment of atherosclerosis
US20130303436A1 (en) * 2012-12-06 2013-11-14 Stealth Peptides Internatioanl, Inc. Peptide therapeutics and methods for using same

Also Published As

Publication number Publication date
WO2015183984A2 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
HK1215934A1 (en) Peptide therapeutics and methods for using same
WO2015183995A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
HK1198869A1 (en) Combination treatments for hepatitis c
HK1249011A1 (en) Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof and methods of using the same
MY199968A (en) Formulations of an lsd1 inhibitor
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
PH12015502002B1 (en) Tripeptide epoxy ketone protease inhibitors
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
MX369818B (en) Selective pyy compounds and uses thereof.
MX2023003124A (en) Ophthalmic pharmaceutical compositions and uses relating thereto.
CY1119007T1 (en) COMPOSITIONS AND METHODS OF Pulmonary Hypertension Treatment
HK1202448A1 (en) Topical formulation for administering a compound
JO3326B1 (en) Tripeptide Epoxy Ketone Protease Inhibitors
EA201890507A1 (en) COMBINATION OF ANTI-VIRAL DIRECT ACTION AND RIBAVIRIN FOR THE TREATMENT OF PATIENTS WITH HCV
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
SA519410993B1 (en) Antibacterial activity of galactooligosaccharide and xylitol in dermatological treatments
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
MX2022013450A (en) Pharmaceutical formulations.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800496

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 27.02.2017)

122 Ep: pct application non-entry in european phase

Ref document number: 15800496

Country of ref document: EP

Kind code of ref document: A2